Is ABEO or GANX more profitable?

Abeona Therapeutics' return on equity of -41.69% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -41.69% -30.36% Gain Therapeutics N/A -161.59% -118.36%

Does the media favor ABEO or GANX?

In the previous week, Gain Therapeutics had 1 more articles in the media than Abeona Therapeutics. MarketBeat recorded 3 mentions for Gain Therapeutics and 2 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 1.60 beat Gain Therapeutics' score of 0.63 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GANX or FATE?

In the previous week, Fate Therapeutics had 4 more articles in the media than Gain Therapeutics. MarketBeat recorded 7 mentions for Fate Therapeutics and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.63 beat Fate Therapeutics' score of 0.52 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GANX or BBOT more profitable?

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% BridgeBio Oncology Therapeutics N/A -46.90% -42.17%

Does the media prefer XFOR or GANX?

In the previous week, X4 Pharmaceuticals had 5 more articles in the media than Gain Therapeutics. MarketBeat recorded 8 mentions for X4 Pharmaceuticals and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.63 beat X4 Pharmaceuticals' score of 0.48 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RCKT or GANX more profitable?

Rocket Pharmaceuticals' return on equity of -52.77% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -52.77% -44.92% Gain Therapeutics N/A -161.59% -118.36%

Does the media favor RCKT or GANX?

In the previous week, Rocket Pharmaceuticals had 4 more articles in the media than Gain Therapeutics. MarketBeat recorded 7 mentions for Rocket Pharmaceuticals and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.63 beat Rocket Pharmaceuticals' score of 0.21 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Gain Therapeutics (GANX) Competitors

$1.32 -0.09 (-6.38%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$1.36 +0.03 (+2.65%)

As of 10/14/2026 07:59 PM Eastern

Compare

GANX vs. ABEO, FATE, BBOT, XFOR, and RCKT

Should you buy Gain Therapeutics stock or one of its competitors? Gain Therapeutics's main competitors and comparable companies include Abeona Therapeutics (ABEO), Fate Therapeutics (FATE), BridgeBio Oncology Therapeutics (BBOT), X4 Pharmaceuticals (XFOR), and Rocket Pharmaceuticals (RCKT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gain Therapeutics compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Abeona Therapeutics' return on equity of -41.69% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Gain Therapeutics	N/A	-161.59%	-118.36%

Abeona Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 381.65%. Gain Therapeutics has a consensus price target of $7.67, indicating a potential upside of 480.81%. Given Gain Therapeutics' higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Gain Therapeutics had 1 more articles in the media than Abeona Therapeutics. MarketBeat recorded 3 mentions for Gain Therapeutics and 2 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 1.60 beat Gain Therapeutics' score of 0.63 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Abeona Therapeutics has higher revenue and earnings than Gain Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$25.52M	9.77	$71.18M	-$1.09	N/A
Gain Therapeutics	$50K	1,152.10	-$20.16M	-$0.50	N/A

Abeona Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Summary

Abeona Therapeutics beats Gain Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Gain Therapeutics compare to Fate Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Gain Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

In the previous week, Fate Therapeutics had 4 more articles in the media than Gain Therapeutics. MarketBeat recorded 7 mentions for Fate Therapeutics and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.63 beat Fate Therapeutics' score of 0.52 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gain Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 480.81%. Fate Therapeutics has a consensus target price of $5.90, suggesting a potential upside of 204.12%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Gain Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

Gain Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,152.10	-$20.16M	-$0.50	N/A
Fate Therapeutics	$6.65M	34.96	-$136.32M	-$1.05	N/A

Summary

Fate Therapeutics beats Gain Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Gain Therapeutics compare to BridgeBio Oncology Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Gain Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 480.81%. BridgeBio Oncology Therapeutics has a consensus price target of $22.88, suggesting a potential upside of 688.79%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gain Therapeutics has higher revenue and earnings than BridgeBio Oncology Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,152.10	-$20.16M	-$0.50	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

In the previous week, BridgeBio Oncology Therapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for BridgeBio Oncology Therapeutics and 3 mentions for Gain Therapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 0.70 beat Gain Therapeutics' score of 0.63 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gain Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

Summary

BridgeBio Oncology Therapeutics beats Gain Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Gain Therapeutics compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

In the previous week, X4 Pharmaceuticals had 5 more articles in the media than Gain Therapeutics. MarketBeat recorded 8 mentions for X4 Pharmaceuticals and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.63 beat X4 Pharmaceuticals' score of 0.48 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gain Therapeutics has lower revenue, but higher earnings than X4 Pharmaceuticals. Gain Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$15.85M	15.33	-$79.20M	-$1.20	N/A
Gain Therapeutics	$50K	1,152.10	-$20.16M	-$0.50	N/A

X4 Pharmaceuticals presently has a consensus target price of $11.25, suggesting a potential upside of 359.18%. Gain Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 480.81%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

X4 Pharmaceuticals has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Gain Therapeutics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. X4 Pharmaceuticals' return on equity of -63.05% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
Gain Therapeutics	N/A	-161.59%	-118.36%

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Gain Therapeutics beats X4 Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Gain Therapeutics compare to Rocket Pharmaceuticals?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Rocket Pharmaceuticals' return on equity of -52.77% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
Gain Therapeutics	N/A	-161.59%	-118.36%

Rocket Pharmaceuticals presently has a consensus price target of $7.77, suggesting a potential upside of 251.68%. Gain Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 480.81%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Rocket Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Rocket Pharmaceuticals had 4 more articles in the media than Gain Therapeutics. MarketBeat recorded 7 mentions for Rocket Pharmaceuticals and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.63 beat Rocket Pharmaceuticals' score of 0.21 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gain Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Gain Therapeutics	$50K	1,152.10	-$20.16M	-$0.50	N/A

Summary

Rocket Pharmaceuticals beats Gain Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GANX vs. The Competition

Export

Metric	Gain Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$61.54M	$3.84B	$7.19B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.60%
P/E Ratio	-2.64	9.48	211.42	19.26
Price / Sales	1,152.10	1,168.88	565.60	77.58
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	2.75	16.54	10.51	5.92
Net Income	-$20.16M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-18.27%	-5.80%	-3.49%	-3.85%
1 Month Performance	-22.81%	-12.84%	-7.76%	-6.37%
1 Year Performance	-29.41%	3.05%	0.82%	-6.01%

Gain Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GANX Gain Therapeutics	1.8711 of 5 stars	$1.32 -6.4%	$7.67 +480.8%	-35.3%	$61.54M	$50K	N/A	21
ABEO Abeona Therapeutics	3.0428 of 5 stars	$5.01 -2.0%	$21.00 +319.2%	-18.5%	$292.21M	$5.82M	N/A	226
FATE Fate Therapeutics	2.5805 of 5 stars	$2.29 -5.8%	$5.90 +157.6%	+29.3%	$291.16M	$6.65M	N/A	161
BBOT BridgeBio Oncology Therapeutics	3.8971 of 5 stars	$3.50 -2.8%	$22.88 +553.6%	N/A	$288.63M	N/A	N/A	88
XFOR X4 Pharmaceuticals	2.1469 of 5 stars	$2.77 -4.5%	$11.25 +306.1%	-17.5%	$287.53M	$35.11M	N/A	45	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GANX) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gain Therapeutics (GANX) Competitors

GANX vs. ABEO, FATE, BBOT, XFOR, and RCKT

How does Gain Therapeutics compare to Abeona Therapeutics?

Summary

How does Gain Therapeutics compare to Fate Therapeutics?

Summary

How does Gain Therapeutics compare to BridgeBio Oncology Therapeutics?

Summary

How does Gain Therapeutics compare to X4 Pharmaceuticals?

Summary

How does Gain Therapeutics compare to Rocket Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gain Therapeutics (GANX) Competitors

GANX vs. ABEO, FATE, BBOT, XFOR, and RCKT

How does Gain Therapeutics compare to Abeona Therapeutics?

Is ABEO or GANX more profitable?

Do analysts recommend ABEO or GANX?

Does the media favor ABEO or GANX?

Do institutionals and insiders believe in ABEO or GANX?

Which has better earnings and valuation, ABEO or GANX?

Which has more risk & volatility, ABEO or GANX?

Summary

How does Gain Therapeutics compare to Fate Therapeutics?

Do insiders and institutionals have more ownership in GANX or FATE?

Which has more volatility and risk, GANX or FATE?

Does the media refer more to GANX or FATE?

Do analysts rate GANX or FATE?

Is GANX or FATE more profitable?

Which has preferable earnings and valuation, GANX or FATE?

Summary

How does Gain Therapeutics compare to BridgeBio Oncology Therapeutics?

Do analysts prefer GANX or BBOT?

Is GANX or BBOT more profitable?

Do insiders & institutionals have more ownership in GANX or BBOT?

Which has better valuation & earnings, GANX or BBOT?

Does the media prefer GANX or BBOT?

Which has more risk and volatility, GANX or BBOT?

Summary

How does Gain Therapeutics compare to X4 Pharmaceuticals?

Does the media prefer XFOR or GANX?

Which has higher valuation and earnings, XFOR or GANX?

Do analysts prefer XFOR or GANX?

Which has more risk & volatility, XFOR or GANX?

Is XFOR or GANX more profitable?

Do institutionals and insiders have more ownership in XFOR or GANX?

Summary

How does Gain Therapeutics compare to Rocket Pharmaceuticals?

Is RCKT or GANX more profitable?

Do analysts recommend RCKT or GANX?

Which has more volatility and risk, RCKT or GANX?

Do institutionals & insiders hold more shares of RCKT or GANX?

Does the media favor RCKT or GANX?

Which has stronger earnings and valuation, RCKT or GANX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools